What it sells
Activating an overlooked force in medicine - the patient.
Business model breakdown
Buyer: who owns the budget?
UnverifiedOncology drug developers (clinical development, medical and AI teams) and trial sponsors.
Trigger: what makes them buy now?
Next-gen oncology agents (ADCs, immunotherapies) lack tolerability data between visits to inform dose and safety decisions.
Workflow: what inputs become what output?
Patients or caregivers do a 1-2 minute home check-in; clinicians review and confirm grading in-flow; platform produces dose-aligned longitudinal, AI-ready datasets.
Distribution: how it reaches customers
Sales-led: "Get in touch" and downloadable overview; deploys as an overlay on existing trials and care programs.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.